| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | TSC2; TSC4; Tuberin; Tuberous sclerosis 2 protein |
| Clonality | |
| Concentration | |
| Formulation | |
| Gene ID | |
| Host | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human Tuberin/TSC2. AA range:905-954 |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Storage | |
| Target |
Product Overview
Primary AntibodyThis antibody targets TSC2 and detects endogenous levels of TSC2 protein.
Validated Applications
| Application | Dilution Guidance |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| Immunofluorescence (IF) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Antibody Specifications
| Target | TSC2 |
|---|---|
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse, Rat |
| Purification | Affinity Purification |
| Molecular Weight | ~200.7 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human Tuberin/TSC2. AA range:905-954 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 7249; Rat: 24855 |
| UniProt | P49815 (Human: P49815; Mouse: Q61037; Rat: P49816) |
Scientific Background
Mutations in TSC2 lead to tuberous sclerosis complex. Its gene product is believed to be a tumor suppressor and is able to stimulate specific GTPases. The protein associates with hamartin in a cytosolic complex, possibly acting as a chaperone for hamartin. Alternative splicing results in multiple transcript variants encoding different isoforms.
Alternative Names
TSC2; TSC4; Tuberin; Tuberous sclerosis 2 protein
Safety & Handling
| Target | TSC2 |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Reactivity | Human, Mouse, Rat |
| Purification | Affinity Purification |
| Molecular Weight | ~200.7 kDa |
| Concentration | 1 mg/ml |
| Immunogen | The antiserum was produced against synthesized peptide derived from human Tuberin/TSC2. AA range:905-954 |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Gene ID | Human: 7249; Rat: 24855 |
| UniProt | P49815 (Human: P49815; Mouse: Q61037; Rat: P49816) |
Optimized working dilutions depend on sample type and detection system. Titration is recommended.
| Application | Dilution Note |
|---|---|
| Western Blot (WB) | Refer to datasheet for recommended working dilution |
| Immunohistochemistry (IHC) | Refer to datasheet for recommended working dilution |
| Immunofluorescence (IF) | Refer to datasheet for recommended working dilution |
| ELISA | Refer to datasheet for recommended working dilution |
Mutations in TSC2 lead to tuberous sclerosis complex. Its gene product is believed to be a tumor suppressor and is able to stimulate specific GTPases. The protein associates with hamartin in a cytosolic complex, possibly acting as a chaperone for hamartin. Alternative splicing results in multiple transcript variants encoding different isoforms.
Alternative Names
TSC2; TSC4; Tuberin; Tuberous sclerosis 2 protein
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
